A novel and selective fluorescent ligand for the study of adenosine A 2B receptors.

Fluorescent ligands have proved to be powerful tools in the study of G protein-coupled receptors in living cells. Here we have characterized a new fluorescent ligand PSB603-BY630 that has high selectivity for the human adenosine A _2B receptor (A _2B R). The A _2B R appears to play an important role in regulating immune responses in the tumor microenvironment. Here we have used PSB603-BY630 to monitor specific binding to A _2B Rs in M1- and M2-like macrophages derived from CD14+ human monocytes. PSB603-BY630 bound with high affinity (18.3 nM) to nanoluciferase-tagged A _2B Rs stably expressed in HEK293G cells. The ligand exhibited very high selectivity for the A _2B R with negligible specific-binding detected at NLuc-A _2A R, NLuc-A ₁ R, or NLuc-A ₃ R receptors at concentrations up to 500 nM. Competition binding studies showed the expected pharmacology at A _2B R with the A _2B R-selective ligands PSB603 and MRS-1706 demonstrating potent inhibition of the specific binding of 50 nM PSB603-BY630 to A _2B R. Functional studies in HEK293G cells using Glosensor to monitor G _s -coupled cyclic AMP responses indicated that PSB603-BY630 acted as a negative allosteric regular of the agonist responses to BAY 60-6583. Furthermore, flow cytometry analysis confirmed that PSB603-BY630 could be used to selectively label endogenous A _2B Rs expressed on human macrophages. This ligand should be an important addition to the library of fluorescent ligands which are selective for the different adenosine receptor subtypes, and will enable study of the role of A _2B Rs on immune cells in the tumor microenvironment.
(© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)